Quantcast

Latest BD Diagnostics Stories

2011-08-03 07:00:00

BALTIMORE and CAMBRIDGE, England, Aug. 3, 2011 /PRNewswire/ -- BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), and Lab21, a global leader in personalized healthcare, announced today a collaboration to develop a state-of-the-art molecular diagnostic assay to detect the life-threatening Aspergillus fungus using the new fully automated BD MAX(TM) Molecular Testing System. "The potential to detect Aspergillus in blood using...

2011-08-02 05:00:00

FRANKLIN LAKES, N.J., Aug. 2, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.014 billion for the third fiscal quarter ended June 30, 2011, representing an increase of 10.0 percent from the prior-year period. On a foreign currency-neutral basis, revenues increased 4.8 percent. "We are pleased with our solid results this quarter, with all three segments contributing to growth," said...

2011-07-26 15:01:00

FRANKLIN LAKES, N.J., July 26, 2011 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that, in accordance with its long-term succession planning, it has elected Vincent A. Forlenza as Chief Executive Officer and President, effective October 1, 2011. Mr. Forlenza will also become a member of the Board at that time. Also effective October 1, current BD Chairman and Chief Executive Officer...

2011-05-19 13:34:00

BALTIMORE, May 19, 2011 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), today announced the U.S. launch of the BD MAX(TM) for use as an open system. BD MAX is the first and only fully automated, bench-top molecular system designed to perform a broad range of molecular tests. This includes in vitro diagnostic (IVD) assays, but also user-defined protocols and life science research applications. The BD MAX System gives clinical laboratory...

2011-05-09 07:00:00

BALTIMORE and LIEGE, Belgium, May 9, 2011 /PRNewswire/ -- BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), and Diagenode SA, an international biotech company based in Belgium, announced today an agreement to co-develop seven initial molecular diagnostic assays on the BD MAX(TM) System for pathogens associated with respiratory, enteric and central nervous system diseases. "Our agreement with Diagenode represents the first...

2011-04-26 15:01:00

FRANKLIN LAKES, N.J., April 26, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.922 billion for the second fiscal quarter ended March 31, 2011, representing an increase of 6.8 percent from the prior-year period. On a foreign currency-neutral basis, revenue increased 4.6 percent, despite an unfavorable comparison to the prior year of about 2.3 percentage points due to strong sales...

2011-02-07 15:04:00

FRANKLIN LAKES, N.J., Feb. 7, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.842 billion for the first fiscal quarter ended December 31, 2010, representing a decrease of 1.4 percent from the prior-year period. On a foreign currency-neutral basis, revenue decreased 1.5 percent. The revenue decline reflects an unfavorable comparison to the prior year of about 4 percentage points due...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related